Document:

Registration Rights Agreement

 Exhibit 10.13 
 REGISTRATION RIGHTS AGREEMENT 
 THIS REGISTRATION
RIGHTS AGREEMENT (the “Agreement”) is made as of this 14th day of March, 2008, by and among Medidata Solutions, Inc., a Delaware corporation (together with any successor
thereto, “Medidata”), and Shareholder Representative Services LLC, as representative (the “Shareholder Representative”) of the former holders of shares of capital stock of Fast Track Systems, Inc., a
California corporation (“Fast Track”). Terms not otherwise defined herein shall have the meanings set forth in the Merger Agreement (as defined below). 
 WHEREAS, Medidata, Fast Track, the Shareholder Representative and FT Acquisition Corp., a California corporation and
a wholly-owned subsidiary of Medidata (“Merger Sub”), have entered into an Agreement and Plan of Merger (the “Merger Agreement”), dated as of February 13, 2008, providing for the merger of Merger
Sub with and into Fast Track (the “Merger”), with Fast Track surviving the Merger as a wholly-owned subsidiary of Medidata; 
 WHEREAS, pursuant to the Merger Agreement, Medidata has agreed to grant the former holders of capital stock of Fast Track certain registration rights, on the terms and conditions set forth in this
Agreement; 
 WHEREAS, Fast Track and the former holders of shares of Fast Track have requested and
directed, pursuant to the Merger Agreement and the agreements and documents referred to therein, that the Shareholder Representative enter into this Agreement on the terms set forth below on their behalf, which terms of this Agreement have been
reviewed and approved by Fast Track and such former shareholders and legal counsel of their choice acting on their behalf; 
 WHEREAS, it is a condition to the Closing under the Merger Agreement that the parties hereto execute and deliver this Agreement; 
 NOW THEREFORE, in consideration of the foregoing and the mutual covenants and agreements hereinafter
set forth, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows: 
 1. Certain Definitions. As used in this Agreement, the following terms shall have the following respective meanings: 
 “Affiliate” of any Person means a Person that directly or indirectly, through one or more intermediaries, controls, is controlled by or is under common control with the first mentioned Person.
A Person shall be deemed to control another Person if such first Person possesses directly or indirectly the power to direct, or cause the direction of, the management and policies of the second Person, whether through the ownership of voting
securities, by contract or otherwise. 
 “Commission” means the United States Securities and Exchange Commission, or
any other federal agency at the time administering the Securities Act and the Exchange Act. 
  

 1. 

 “Exchange Act” means the Securities Exchange Act of 1934, as amended, or any
similar successor federal statute, and the rules and regulations of the Commission thereunder, all as the same shall be in effect at the time. 
 “Existing Investors” means the “Investors,” as such term is defined in the Existing Registration Rights Agreement. 
 “Existing Registration Rights Agreement” means the Amended and Restated Registration Rights Agreement dated as of May 27, 2004 by and among Medidata and the Persons listed on the signature
pages thereto. 
 “Holder” means a Person who was, immediately prior to the Effective Time, a holder of Company
Capital Stock, Company Options or Company Warrants. 
 “Medidata Common Stock” means Medidata’s Common Stock,
$0.01 par value per share, as authorized on the date of this Agreement and any other common equity securities now or hereafter issued by Medidata, and any other shares of stock issued or issuable with respect thereto (whether by way of a stock
dividend or stock split or in exchange for or in replacement of or upon conversion of such shares or otherwise in connection with a combination of shares, recapitalization, merger, consolidation or other corporate reorganization). 
 “Person” means an individual, a corporation, a partnership, a joint venture, a trust, an unincorporated organization, a limited
liability company, a government and any agency or political subdivision thereof. 
 “Registrable Securities” shall
mean (a) any shares of Medidata Common Stock held by a Holder on the date hereof, (b) any shares of Medidata Common Stock subject to acquisition by a Holder upon conversion of any securities of Medidata held by such Holder on the date
hereof that are convertible into or exercisable or exchangeable for Medidata Common Stock, and (c) any other securities issued and issuable with respect to any such shares described in clauses (a) and (b) above by way of a stock
dividend or stock split or in connection with a combination of shares, recapitalization, merger, consolidation or other reorganization; provided, however, that notwithstanding anything to the contrary contained herein, “Registrable
Securities” shall not at any time include any securities (i) sold pursuant to an effective registration statement under the Securities Act, (ii) sold to the public pursuant to Rule 144 promulgated under the Securities Act or
(iii) which could then be sold in their entirety pursuant to Rule 144 under the Securities Act. 
 “Securities
Act” means the Securities Act of 1933, as amended, or any similar successor federal statute, and the rules and regulations of the Commission thereunder, all as the same shall be in effect at the time. 
 2. Piggyback Registrations. If at any time or times after the date hereof (other than in connection with Medidata’s initial public offering)
Medidata shall seek to register any shares of Medidata Common Stock under the Securities Act for sale to the public for its own account or on the account of others (except with respect to registration statements on Form S-4, Form S-8 or another form
not available for registering the Registrable Securities for sale to the public), Medidata will promptly give written notice thereof to all Holders of Registrable Securities then holding 10,000 or more shares of Medidata Common Stock. The number of
shares of Medidata 

  

 2. 

 
Common Stock held by each holder shall be deemed to be the total number of shares of Medidata Common Stock then owned by such Holder, plus the total number
of shares of Medidata Common Stock issuable to such Holder upon conversion of any convertible securities of Medidata held by such Holder or the exercise of any other vested options, warrants or subscription rights of Medidata then owned by such
Holder. If within twenty (20) days after their receipt of such notice one or more Holders request the inclusion of some or all of the Registrable Securities owned by them in such registration, Medidata will use its reasonable best efforts to
effect the registration under the Securities Act of such Registrable Securities. In the case of the registration of shares of capital stock by Medidata in connection with any underwritten public offering, if the underwriter(s) determines that
marketing factors require a limitation on the number of Registrable Securities to be offered, then, subject to the following sentence, Medidata shall not be required to register Registrable Securities of the Holders in excess of the amount, if any,
of shares of the capital stock which the principal underwriter of such underwritten offering shall reasonably and in good faith agree to include in such offering in addition to any amount to be registered for the account of Medidata. Subject to the
preceding sentence, if any limitation of the number of shares of Registrable Securities to be registered by the Holders is required pursuant to this Section 2, the number of shares to be excluded from such registration shall be
determined in the following sequence: (i) first, securities sought to be included by any Persons not having any contractual, incidental “piggyback” rights, (ii) second, securities sought to be included by any Persons (other than
the Holders or the Existing Investors) having contractual, incidental “piggyback” rights pursuant to an agreement which is not this Agreement or the Existing Registration Rights Agreement, (iii) third, Registrable Securities sought to
be included by the Holders under this Section 2 as determined on a pro rata basis (based upon the respective holdings of Registrable Securities by such Holders) and (iv) fourth, Registrable Securities sought to be included by the
Existing Investors pursuant to the Existing Registration Rights Agreement. Notwithstanding the foregoing provisions or any other provisions of this Agreement, Medidata may withdraw any registration statement referred to in this Section 2
without thereby incurring any liability to the Holders of Registrable Securities. The piggyback registration rights under this Section 2 shall apply only to Holders of Registrable Securities holding 10,000 or more shares of Medidata Common
Stock on the date of the notice referenced in the first sentence of this Section 2 (as adjusted for any stock dividends, combinations, splits, recapitalizations and the like after the date of the Merger Agreement). For the avoidance of doubt, a
Holder may aggregate his, her or its shares of Medidata Common Stock with the shares of Medidata’s Common Stock held by such Holder’s Affiliates for purposes of reaching such 10,000 share threshold. 
 3. Further Obligations of Medidata. Whenever Medidata is required hereunder to register any Registrable Securities, it agrees that it shall also
do the following: 
 (a) Pay all expenses of such registrations and offerings (exclusive of underwriting fees, commissions, discounts
and allowances) and the reasonable fees and expenses of not more than one independent counsel for the Holders in connection with any registrations hereunder; 
 (b) Use its reasonable best efforts to keep the registration statement filed with the Commission in connection with such offering effective until the Holder or Holders have completed the distribution described
in the registration statement relating thereto (but for no 

  

 3. 

 
more than 120 days or such lesser period in which all Registrable Securities registered pursuant thereto are sold) and to comply with the provisions of the
Securities Act with respect to the sale of securities covered by said registration statement for such period; 
 (c) Furnish to each
selling Holder such copies of each preliminary and final prospectus and such other documents as such Holder may reasonably request to facilitate the public offering of its Registrable Securities; 
 (d) Enter into any reasonable underwriting agreement required by the proposed underwriter, if any, in such form and containing such terms as are
customary; provided, however, that no Holder shall be required to make any representations or warranties other than with respect to its title to the Registrable Securities and with respect to any written information provided by the Holder to
Medidata, and if the underwriter requires that representations or warranties be made and that indemnification be provided, Medidata shall make all such representations and warranties and provide all such indemnities, including, without limitation,
in respect of Medidata’s business, operations and financial information and the disclosures relating thereto in the prospectus; 
 (e) Use its reasonable best efforts to register or qualify the securities covered by said registration statement under the securities or “blue sky” laws of such jurisdictions as any selling Holder may reasonably request;
provided, that Medidata shall not be required to register or qualify the securities in any jurisdictions in which such registration or qualification would require it to qualify to do business therein; 
 (f) Immediately notify each selling Holder, at any time when a prospectus relating to his, her or its Registrable Securities is required to be
delivered under the Securities Act, of the happening of any event as a result of which such prospectus contains an untrue statement of a material fact or omits any material fact necessary to make the statements therein, in light of the circumstances
under which they were made, not misleading, and, at the request of any such selling Holder, prepare a supplement or amendment to such prospectus so that, as thereafter delivered to the purchasers of such Registrable Securities, such prospectus will
not contain any untrue statement of a material fact or omit to state any material fact necessary to make the statements therein not misleading, in light of the circumstances then existing; 
 (g) Cause all such Registrable Securities to be listed on each securities exchange or quotation system on which similar securities issued by
Medidata are then listed or quoted; 
 (h) Otherwise use its reasonable best efforts to comply with the securities laws of the United
States and other applicable jurisdictions and all applicable rules and regulations of the Commission and comparable governmental agencies in other applicable jurisdictions and make generally available to its holders, in each case as soon as
practicable, but not later than forty-five (45) days after the close of the period covered thereby, an earnings statement of Medidata which will satisfy the provisions of Section 11(a) of the Securities Act; 
 (i) If the offering is underwritten, obtain and furnish to each selling Holder, immediately prior to the effectiveness of the registration
statement and, at the time of delivery of 

  

 4. 

 
any Registrable Securities sold pursuant thereto, (i) a legal opinion from Medidata’s outside counsel, and (ii) a cold comfort letter from
Medidata’s independent public accountants, in each case in customary form and covering such matters of the type customarily covered by such opinions or cold comfort letters as the Holders of a majority of the Registrable Securities being sold
may reasonably request; and 
 (j) Otherwise cooperate with the underwriter or underwriters, the Commission and other regulatory
agencies and take all actions and execute and deliver or cause to be executed and delivered all documents necessary to effect the registration of any Registrable Securities hereunder. 
 4. Indemnification; Contribution. 
 (a) Incident to any registration of any Registrable Securities under the Securities Act pursuant to this Agreement, Medidata will indemnify and hold harmless each underwriter and each Holder who offers or sells any such Registrable
Securities in connection with such registration statement (including such Holder’s partners (including partners of partners and stockholders of any such partners), and directors, officers, employees, representatives and agents of any of them (a
“Selling Holder”), and each person who controls any of them within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act (a “Controlling Person”)) from and against
any and all losses, claims, damages, expenses and liabilities, joint or several (including any investigation, legal and other expenses incurred in connection with, and any amount paid in settlement of, any action, suit or proceeding or any claim
asserted, as the same are incurred), to which they, or any of them, may become subject under the Securities Act, the Exchange Act or other federal or state statutory law or regulation, at common law or otherwise, insofar as such losses, claims,
damages or liabilities arise out of or are based on (i) any untrue statement or alleged untrue statement of a material fact contained in such registration statement (including any related preliminary or definitive prospectus, or any amendment
or supplement to such registration statement or prospectus), (ii) any omission or alleged omission to state in such document a material fact required to be stated in it or necessary to make the statements in it not misleading, or (iii) any
violation by Medidata of the Securities Act, any state securities or “blue sky” laws or any rule or regulation thereunder in connection with such registration; provided, however, that Medidata will not be liable to the extent that such
loss, claim, damage, expense or liability arises from and is based on an untrue statement or omission or alleged untrue statement or omission made in reliance on and in conformity with information furnished in writing to Medidata by such
underwriter, Selling Holder or Controlling Person expressly for use in such registration statement. With respect to such untrue statement or omission or alleged untrue statement or omission in the information furnished in writing to Medidata by such
Selling Holder expressly for use in such registration statement, such Selling Holder will indemnify and hold harmless each underwriter, Medidata (including its directors, officers, employees, representatives and agents) and each other Holder
(including such Holder’s partners (including partners of partners and stockholders of such partners) and directors, officers, employees, representatives and agents of any of them, and each person who controls any of them within the meaning of
Section 15 of the Securities Act or Section 20 of the Exchange Act), from and against any and all losses, claims, damages, expenses and liabilities, joint or several, to which they, or any of them, may become subject under the Securities
Act, the Exchange Act or other federal or state statutory law or regulation, at common law or otherwise to the same extent 

  

 5. 

 
provided in the immediately preceding sentence. In no event, however, shall the liability of a Selling Holder for indemnification under this
Section 4(a) exceed the net proceeds received by such Selling Holder from its sale of Registrable Securities under such registration statement. 
 (b) If the indemnification provided for in Section 4(a) above for any reason is held by a court of competent jurisdiction to be unavailable to an indemnified party in respect of any losses, claims,
damages, expenses or liabilities referred to therein, then each indemnifying party under this Section 4, in lieu of indemnifying such indemnified party thereunder, shall contribute to the amount paid or payable by such indemnified party
as a result of such losses, claims, damages, expenses or liabilities (i) in such proportion as is appropriate to reflect the relative benefits received by Medidata, the Selling Holders and the underwriters from the offering of the Registrable
Securities or (ii) if the allocation provided by clause (i) above is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i) above but also the relative
fault of Medidata, the Selling Holders and the underwriters in connection with the statements or omissions which resulted in such losses, claims, damages, expenses or liabilities, as well as any other relevant equitable considerations The relative
benefits received by Medidata, the Selling Holders and the underwriters shall be deemed to be in the same respective proportions that the net proceeds from the offering received by Medidata and the Selling Holders and the underwriting discount
received by the underwriters, in each case as set forth in the table on the cover page of the applicable prospectus, bear to the aggregate public offering price of the Registrable Securities. The relative fault of Medidata, the Selling Holders and
the underwriters shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by Medidata, the
Selling Holders or the underwriters and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. 
 Medidata, the Selling Holders, and the underwriters agree that it would not be just and equitable if contribution pursuant to this
Section 4(b) were determined by pro rata or per capita allocation or by any other method of allocation which does not take account of the equitable considerations referred to in the immediately preceding paragraph. In no event, however,
shall a Selling Holder be required to contribute any amount under this Section 4(b) in excess of the net proceeds received by such Selling Holder from its sale of Registrable Securities under such registration statement. No person found
guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not found guilty of such fraudulent misrepresentation. 
 (c) The amount paid by an indemnifying party or payable to an indemnified party as a result of the losses, claims, damages and liabilities
referred to in this Section 4 shall be deemed to include, subject to the limitations set forth above, any legal or other expenses reasonably incurred by such indemnified party in connection with investigating or defending any such action
or claim, payable as the same are incurred. The indemnification and contribution provided for in this Section 4 will remain in full force and effect regardless of any investigation made by or on behalf of the indemnified parties or any
officer, director, employee, agent or Controlling Person of the indemnified parties. No indemnifying party, in the defense of any such claim or litigation, shall enter into a consent of entry of any judgment or enter into a settlement without the
consent of the indemnified party, which consent will not be unreasonably withheld. 
  

 6. 

 (d) Notwithstanding the foregoing, to the extent the provisions on indemnification and
contribution contained in the underwriting agreement entered into in connection with an underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control. 
 5. Rule 144 and Rule 144A Requirements. In the event that Medidata becomes subject to Section 13 or Section 15(d) of the Exchange Act,
Medidata shall use its reasonable best efforts to take all action as may be required as a condition to the availability of Rule 144 or Rule 144A under the Securities Act (or any successor or similar exemptive rules hereafter in effect). Medidata
shall furnish to any Holder, within fifteen (15) days of a written request, a written statement executed by Medidata as to the steps it has taken to comply with the current public information requirement of Rule 144 or Rule 144A or such
successor rules. 
 6. Miscellaneous. 
 (a) Restrictive Legend. Each certificate representing Registrable Securities shall be stamped or otherwise imprinted with a legend substantially in the following form: 
 “THIS SECURITY HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS AND MAY NOT BE TRANSFERRED OR
OTHERWISE DISPOSED OF UNLESS IT HAS BEEN REGISTERED UNDER SUCH ACT AND ALL SUCH APPLICABLE LAWS OR AN EXEMPTION FROM REGISTRATION IS AVAILABLE.” 
 (b) Amendments, Waivers and Consents. For the purposes of this Agreement and all agreements executed pursuant hereto, no course of dealing between or among any of the parties hereto and no delay on the part of
any party hereto in exercising any rights hereunder or thereunder shall operate as a waiver of the rights hereof and thereof. This Agreement may not be amended or modified or any provision hereof waived without the written consent of Medidata and
the Shareholder Representative. 
 (c) Governing Law. This Agreement shall be governed by, construed and enforced in accordance with
the laws of the State of Delaware without regard to the principles thereof relating to conflict of laws. 
 (d) Section Headings and
Gender. The descriptive headings in this Agreement have been inserted for convenience only and shall not be deemed to limit or otherwise affect the construction of any provision hereof. The use in this Agreement of the masculine pronoun in
reference to a party hereto shall be deemed to include the feminine or neuter, and vice versa, as the context may require. 
 (e)
Counterparts. This Agreement may be executed simultaneously in any number of counterparts (including by facsimile or pdf), each of which when so executed and delivered shall be taken to be an original, but such counterparts shall together
constitute but one and the same document. 
 (f) Notices and Demands. All notices, claims, certificates, requests, demands and other
communications hereunder shall be in writing and shall be deemed to have 

  

 7. 

 
been duly given if personally delivered or if sent by nationally-recognized overnight courier, by telecopy, or by registered or certified mail, return
receipt requested and postage prepaid, addressed as follows: 
  

	 	(i)	if to Medidata, to: 

 Medidata
Solutions, Inc. 
 79 Fifth Avenue 
 New York, New York 10003 
 Telephone: 212-918-1800 
 Attention: General Counsel 
 Fax: 212-466-4177 
 with a copy to: 
 Fulbright & Jaworski LLP 
 666 Fifth Avenue 
 New York, New York 10103 
 Telephone: 212-318-3400 
 Attention: Paul Jacobs, Esq. 
 Fax: 212-318-3400 
  

	 	(ii)	if to the Shareholder Representative, to: 

 Shareholder Representative Services LLC 
 999 18th Street, Suite 1825 
 Denver, CO 80202 
 Attention: Managing Director 
 Fax: 720-306-3015 
 and 
 (iii) if to a Holder, at the
mailing address for notice as set forth in the books and records of Medidata, or at any other address designated by a Holder to Medidata in writing. 
 Any such notice or communication shall be deemed to have been received (i) in the case of personal delivery, on the date of such delivery if a business day or, if not a business day, the next succeeding business
day, (ii) in the case of nationally-recognized overnight courier, on the next business day after the date when sent, (iii) in the case of telecopy transmission, when received if a business day or, if not a business day, the next succeeding
business day, and (iv) in the case of mailing, on the third business day following that on which the piece of mail containing such communication is posted. 
 (g) Severability; Assignment. Whenever possible, each provision of this Agreement shall be interpreted in such a manner as to be effective and valid under applicable law, but if any provision of this Agreement
shall be deemed prohibited or invalid under such applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, 

  

 8. 

 
and such prohibition or invalidity shall not invalidate the remainder of such provision or the other provisions of this Agreement. The rights and obligations
of the parties hereunder are not assignable. 
 (h) Integration. This Agreement and the Merger Agreement, including the exhibits,
documents and instruments referred to herein or therein, constitutes the entire agreement, and supersedes all other prior or contemporaneous agreements and understandings, both written and oral, among the parties with respect to the subject matter
hereof. 
 [SIGNATURE PAGES FOLLOW] 
  

 9. 

 IN WITNESS WHEREOF, the parties hereto
have caused this Registration Rights Agreement to be duly executed as of the date first set forth above. 
  

			
	MEDIDATA SOLUTIONS, INC.
		
	By:	 	 /s/ Tarek Sherif

	Name:	 	Tarek Sherif
	Title:	 	Chief Executive Officer
	
	 SHAREHOLDER REPRESENTATIVE SERVICES LLC,
 as Shareholder Representative

		
	By:	 	 /s/ Mark A. Vogel

	Name:	 	Mark A. Vogel
	Title:	 	Managing DirectorForm of Executive Change in Control Agreement

 Exhibit 10.14 
 MEDIDATA SOLUTIONS, INC. 
 EXECUTIVE CHANGE IN CONTROL AGREEMENT 
 WITH [NAME OF EXECUTIVE] 
 AGREEMENT made as
of the              day of January     , 2009, by and between MEDIDATA SOLUTIONS, INC. (“Company”) and
                                        
(“Executive”). 
 1. Background. This Agreement is intended to provide Executive with certain payments and benefits upon an involuntary
termination of Executive’s employment or the occurrence of certain other circumstances that may affect Executive’s employment following a change in control of the Company. The Company believes this Agreement will help ensure
Executive’s undivided focus on the business of the Company during a period of transition and uncertainty and thereby enhance shareholder value. 
 2.
Certain Defined Terms. The following terms have the following meanings when used in this Agreement. 
 2.1 “Accrued
Compensation” means, as of any date, (1) the unpaid amount, if any, of Executive’s previously earned base salary, (2) the unpaid amount, if any, of the bonus earned by Executive for the preceding year, and (3) additional
payments or benefits, if any, earned by Executive under and in accordance with any employee plan, program or arrangement of or with the Company or an Affiliate (other than this Agreement). 
 2.2 “Affiliate” means an entity at least 50% of the voting, capital or profits interests of which are owned directly or indirectly by Company.

 2.3 “Benefit Continuation Coverage” means continuing group health and group life insurance coverage for Executive and, where
applicable, Executive’s covered spouse and covered eligible dependents for a specified period following the termination of Executive’s Employment with Company and its Affiliates at the same benefit and contribution levels in effect for
active senior executives of the Company as in effect from time to time during such period. Unless sooner terminated, Benefit Continuation Coverage will be subject to early termination if and when Executive becomes entitled to comparable coverage
from another employer. 
 2.4 “Board” means the Board of Directors of the Company. 
 2.5 “Cause” means (1) Executive’s willful failure (except where due to physical or mental incapacity) or refusal to perform in any
material respect the duties and responsibilities of Executive’s employment which is not corrected within ten days following written notice of such conduct by the Company; (2) misappropriation by Executive of the assets or business
opportunities of the Company or its Affiliates; (3) embezzlement or fraud committed by Executive, at Executive’s direction, or with Executive’s prior personal knowledge; or (4) Executive’s conviction of, or plea of guilty or
nolo contendere to, the commission of a felony. 
 2.6 “Change in Control” means the occurrence of any of the following
(excluding the completion of the Company’s initial public offering): 
 (a) any person (within the meaning of Section 13(d)(3) or
14(d)(2) of the Securities Exchange Act of 1934, as amended (“Exchange Act”)) other than the Company, any employee benefit plan of the Company, any entity owned directly or indirectly by the shareholders of the Company in substantially the
same proportion as their ownership of stock of the Company or any person who becomes a beneficial owner directly or indirectly of securities of the Company pursuant to a transaction described in (b) below, becomes the beneficial owner (within
the meaning of Rule 13d-3 promulgated under the Exchange Act) of securities of the Company (not including in the securities beneficially owned by such person any securities acquired directly from the Company or its affiliates) representing 50% or
more of the combined voting power of the Company’s then outstanding voting securities; 
  

 - 1 - 

 (b) consolidation, merger or reorganization of the Company, unless (1) the stockholders of Company
immediately before such consolidation, merger or reorganization own, directly or indirectly, at least a majority of the combined voting power of the outstanding voting securities of the corporation or other entity resulting from such consolidation,
merger or reorganization, (2) individuals who were members of the Board immediately prior to the execution of the agreement providing for such consolidation, merger or reorganization constitute a majority of the board of directors of the
surviving corporation or of a corporation directly or indirectly beneficially owning a majority of the voting securities of the surviving corporation, and (3) no person beneficially owns more than 50% of the combined voting power of the then
outstanding voting securities of the surviving corporation (other than a person who is (A) Company or a subsidiary of Company, (B) an employee benefit plan maintained by Company, the surviving corporation or any subsidiary, or (C) the
beneficial owner of 50% or more of the combined voting power of the outstanding voting securities of Company immediately prior to such consolidation, merger or reorganization); 
 (c) the replacement of a majority of the Company’s Board in any given year as compared to the directors who constituted the Company’s Board at
the beginning of such year, and such replacement shall not have been approved by a vote of at least two-thirds of the Company’s Board as constituted at the beginning of such year; 
 (d) sale or other disposition of all or substantially all (50% or more) of the assets of the Company (other than to an entity described in
(b) above); or 
 (e) any other event or transaction which the Board, acting in its discretion, designates is a Change in Control.

 2.7 Code” means the Internal Revenue Code of 1986, as amended. 
 2.8 “Company” means Medidata Solutions, Inc. and any successor thereto. 
 2.9 “Employment” means Executive’s employment with the Company and/or any of its Affiliates. 
 2.10 “Good Reason” means the occurrence of any of the following without the written consent of Executive: (1) a material diminution by
Company or an Affiliate of Executive’s duties or responsibilities in a manner which is inconsistent with Executive’s position prior to a Change in Control or which has or is reasonably likely to have a material adverse effect on
Executive’s status or authority; (2) a relocation by more than 50 miles of Executive’s principal 

  

 - 2 - 

 
place of business; or (3) a reduction by Company or an Affiliate of Executive’s rate of salary or annual incentive opportunity or a breach by
Company or any of its Affiliates of a material provision of any written employment or other agreement with Executive. Before terminating Employment for Good Reason, Executive must specify in writing to the Company (or the successor or acquiring
company) the nature of the act or omission that Executive deems to constitute Good Reason and provide the Company (or the successor or acquiring company) 30 days after receipt of such notice to review and, if required, correct the situation (and
thus prevent Executive’s termination for Good Reason). Notice of termination for Good Reason must be provided, if at all, within 90 days after the occurrence of the event or condition giving rise to such termination. The failure of Executive to
be a senior executive officer of a public company following a Change in Control shall not, by itself, constitute Good Reason. 
 2.11
“Pro Rata Bonus” means the product of (1) the annual incentive award (if any) that would have been earned by Executive for the calendar year in which his Employment terminates if his Employment had not terminated, multiplied by
(2) a fraction, the numerator of which is the number of days elapsed from the beginning of that calendar year until the date his employment terminates, and the denominator of which is 365. 
 2.12 “Salary” means, as of the effective date of the termination of Executive’s Employment, the highest annual rate of Executive’s
salary at any time during the preceding 24 months. 
 3. General Severance Protection. If there has been a Change in Control of the Company, and
either (a) during the period beginning on the date of the execution of the definitive agreement leading to the Change in Control and ending on the date that is twenty four (24) months after the Change in Control, Executive’s
employment is terminated by the Company without Cause, or (b) within twenty four (24) months from and including the date of the Change in Control Executive’s employment is terminated by the Company without Cause or by Executive for
Good Reason, then, subject to Sections 4 and 7, Executive shall receive the following payments and benefits: 
 (a) Executive’s Accrued
Compensation; 
 (b) payment of any business expenses that were previously incurred but not reimbursed and are otherwise eligible for
reimbursement; 
 (c) a cash payment equal to Executive’s Pro Rata Bonus based upon Executive’s target bonus for the year of
termination and payable immediately following such termination of Employment; 
 (d) a single sum cash payment, to be made as soon as
practicable (but not more than thirty days) following termination of employment, of an amount equal to 1.0 times the sum of (1) Executive’s Salary, and (2) Executive’s target annual incentive award for the calendar year in which
his employment terminates (or, if greater, the actual annual incentive award earned by Executive for the preceding calendar year); 
 (e)
Executive will be deemed to have satisfied in full any vesting condition under any then outstanding long-term incentive awards, with the amount payable under any then outstanding performance-based awards being determined at the end of the applicable
performance period as if Executive’s employment had continued; and 
  

 - 3 - 

 (f) Benefit Continuation Coverage for a period of one year from the termination date, which shall be in
addition to and not in lieu of COBRA coverage, provided, however, that, if such coverage is not permitted by the Company’s group health plan or by applicable law, the Company will provide COBRA continuation coverage to Executive and his spouse
and eligible dependents at the Company’s sole expense, if and to the extent they or any of them shall have elected and shall be entitled to receive COBRA continuation coverage. 
 4. Restoration. Any severance payments and benefits paid under Section 3(c) through (f) shall be subject to continuing compliance with any applicable outstanding non-disclosure, non-competition and
non-solicitation covenants made by Executive to the Company. 
 5. Effect of a Change in Control on Options and Other Equity-Based Awards. All
outstanding Company stock options and other Company equity-based awards held by Executive shall become fully vested immediately before the occurrence of a Change in Control if Executive is then still employed by Company or an Affiliate. 

6. Golden Parachute Excise Tax Gross-Up. Gross-Up Payments. 
 6.1 General. Except as otherwise specified in Section 6.10, if any payment or benefit received or to be received by Executive from the Company pursuant to the terms of this Agreement, when combined with
the payments and benefits Executive is entitled to receive under any other plan, program or arrangement (the “Payments”) would be subject to the excise tax (the “Excise Tax”) imposed by Section 4999 of the Internal Revenue
Code (the “Code”) as determined below, the Company shall pay Executive, at the time(s) specified below, an additional amount (the “Gross-Up Payment”) such that the net cost to the Executive for the payment of the Excise Tax
(including any federal, state, and local income tax and the Excise Tax upon the Gross-Up Payment, and any interest, penalties, or additions to tax payable by Executive with respect thereto), shall be equal to 50% of the gross cost, which, absent the
Gross-Up Payment, the Executive would have been required to pay for the Excise Tax (including any federal, state, and local income tax and the Excise Tax upon the Gross-Up Payment, and any interest, penalties, or additions to tax payable by
Executive with respect thereto). 
 6.2 Calculations. For purposes of determining whether any of the Payments shall be subject to the
Excise Tax and the amount of such excise tax: 
 (a) the total amount of the Payments shall be treated as “parachute payments”
within the meaning of section 280G(b)(2) of the Code, and all “excess parachute payments” within the meaning of section 280G(b)(1) of the Code shall be treated as subject to the excise tax, except to the extent that, in the written opinion
of independent counsel or an independent national accounting firm selected by the Company and reasonably acceptable to Executive (“Independent Adviser”), a Payment (in whole or in part) does not constitute a “parachute payment”
within the meaning of section 280G(b)(2) of the Code, or such “excess parachute payments” (in whole or in part) are not subject to the Excise Tax; 
 (b) the amount of the Payments that shall be subject to the Excise Tax shall be equal to the lesser of (1) the total amount of the Payments or (2) the amount of “excess parachute payments” within
the meaning of section 280G(b)(1) of the Code (after applying clause (i), above); and 
  

 - 4 - 

 (c) the value of any non-cash benefits or any deferred payment or benefit shall be determined by the
Independent Adviser in accordance with the principles of section 280G(d)(3) and (4) of the Code. 
 6.3 Tax Rates. For purposes
of determining the amount of the Gross-Up Payment, Executive shall be deemed to pay federal income taxes at the highest marginal rates of federal income taxation applicable to individuals in the calendar year in which the Gross-Up Payment is to be
made and state and local income taxes, if any, at the highest marginal rates of taxation applicable to individuals as are in effect in the state and locality of his residence in the calendar year in which the Gross-Up Payment is to be made, net of
the maximum reduction in federal income taxes that can be obtained from deduction of such state and local taxes, taking into account any limitations applicable to individuals subject to federal income tax at the highest marginal rates. 

6.4 Time of Gross-Up Payments. The Gross-Up Payments provided for in this Section 6.3 shall be made upon the earlier of (a) the
payment to Executive of any Payment or (b) the imposition upon Executive, or any payment by him, of any Excise Tax. 
 6.5
Adjustments to Gross-Up Payments. If it is established pursuant to a final determination of a court or an Internal Revenue Service proceeding or the written opinion of the Independent Adviser that the Excise Tax is less than the amount
previously taken into account hereunder, Executive shall repay the Company, within 30 days of his receipt of notice of such final determination or opinion, the portion of the Gross-Up Payment attributable to such reduction (plus the portion of the
Gross-Up Payment attributable to the Excise Tax and federal, state, and local income tax imposed on the Gross-Up Payment being repaid by Executive if such repayment results in a reduction in Excise Tax or a federal, state, and local income tax
deduction) plus any interest received by Executive on the amount of such repayment, provided that if any such amount has been paid by Executive as an Excise Tax or other tax, he shall cooperate with the Company in seeking a refund of any tax
overpayments, and he shall not be required to make repayments to the Company until the overpaid taxes and interest thereon are refunded to him. 
 6.6 Additional Gross-Up Payment. If it is established pursuant to a final determination of a court or an Internal Revenue Service proceeding or the written opinion of the Independent Adviser that the Excise Tax exceeds the amount
taken into account hereunder (including by reason of any payment the existence or amount of which cannot be determined at the time of the Gross-Up Payment), the Company shall make an additional Gross-Up Payment in respect of such excess within 30
days of the Company’s receipt of notice of such final determination or opinion. 
 6.7 Change in Law or Interpretation. In the
event of any change in or further interpretation of section 280G or 4999 of the Code and the regulations promulgated thereunder, Executive shall be entitled, by written notice to the Company, to request a written opinion of the Independent Adviser
regarding the application of such change or further interpretation to any of the foregoing, and the Company shall use its commercially reasonable efforts to cause such opinion to be rendered as promptly as practicable. 
  

 - 5 - 

 6.8 Fees and Expenses. All fees and expenses of the Independent Adviser incurred in connection
with this section shall be borne by the Company. 
 6.9 Survival. The Company’s obligation to make a Gross-Up Payment with
respect to Payments made or accrued before the termination of this Agreement shall survive the termination of the Agreement unless (1) Executive ‘s employment is terminated by the Company for Cause or voluntarily by Executive without Good
Reason, (2) Executive fails to execute a release in accordance with Section 7 of this Agreement, or (c) Executive fails to comply with the restrictive covenants described in Section 4 of this Agreement, in which event the
Company’s obligation under this Section 6 shall terminate immediately. 
 7. Release of Claims. Notwithstanding anything herein to the
contrary, the Company may condition severance payments or benefits otherwise payable under Section 3(c) through (f) of this Agreement upon the execution and delivery by Executive (or Executive’s beneficiary) of a general release in
favor of Company, its Affiliates and their officers, directors and employees, in such form as the Company may reasonably specify. Any payment or benefit that is so conditioned may be deferred until the expiration of the seven day revocation period
prescribed by the Age Discrimination in Employment Act of 1967, as amended, or any similar revocation period in effect on the effective date of the termination of Executive’s Employment. 
 8. Effect of Other Agreements. This Agreement represents the entire agreement of the parties on the subject matter hereof and shall supersede any and all previous
contracts, arrangements or understandings between Executive and the Company regarding Executive’s termination of employment in connection with a Change in Control. 
 9. No Duty to Mitigate. Except as otherwise specifically provided herein with respect to early termination of Benefit Continuation Coverage, Executive’s entitlement to payments or benefits hereunder is not
subject to mitigation or a duty to mitigate by Executive. 
 10. Amendment. The Company may amend this Agreement, provided, however, that, no such
action which would have the effect of reducing or diminishing Executive’s entitlements under this Agreement shall be effective without the express written consent of Executive. 
 11. Successors and Beneficiaries. 
 11.1 Successors and Assigns of Company. The Company shall
require any successor or assignee, whether direct or indirect, by purchase, merger, consolidation or otherwise, to all or substantially all the business or assets of Company and its subsidiaries taken as a whole, expressly and unconditionally to
assume and agree to perform or cause to be performed Company’s obligations under this Agreement. In any such event, the term “Company,” as used herein shall mean Company, as defined in Section 2 hereof, and any such successor or
assignee. 
 11.2 Executive’s Beneficiary. For the purposes hereof, Executive’s beneficiary will be the person or persons
designated as such in a written beneficiary designation filed with the Company, which may be revoked or revised in the same manner at any time prior to Executive’s death. In the absence of a properly filed written beneficiary designation or if
no designated beneficiary survives Executive, Executive’s estate will be deemed to be the beneficiary hereunder. 
  

 - 6 - 

 11.3 Nonassignability. With the exception of Executive’s beneficiary designation, neither
Executive nor Executive’s beneficiary may pledge, transfer or assign in any way the right to receive payments or benefits hereunder, and any attempted pledge, transfer or assignment shall be void and of no force or effect. 
 12. Legal Fees to Enforce Rights after a Change in Control. If, following a Change in Control, Company fails to comply with any of its obligations under this
Agreement or Company takes any action to declare this Agreement void or unenforceable or institutes any litigation or other legal action designed to deny, diminish or to recover from Executive (or Executive’s beneficiary) the payments and
benefits intended to be provided, then Executive (or Executive’s beneficiary, as the case may be) shall be entitled to select and retain counsel at the expense of Company to represent Executive (or Executive’s beneficiary) in connection
with the good faith initiation or defense of any litigation or other legal action, whether by or against Company or any director, officer, stockholder or other person affiliated with Company or any successor thereto in any jurisdiction. 

13. Not a Contract of Employment. This Agreement shall not be deemed to constitute a contract of employment between Executive and Company or any of its
Affiliates. Nothing contained herein shall be deemed to give Executive a right to be retained in the employ or other service of Company or any of its Affiliates or to interfere with the right of Company or any of its Affiliates to terminate
Executive’s employment at any time. 
 14. Governing Law. This Agreement shall be governed by the laws of the State of New York, excluding its
conflict of law rules. 
 15. Withholding. Company and its Affiliates may withhold from any and all amounts payable under this Agreement such federal,
state and local taxes as may be required to be withheld pursuant to applicable law. 
 16. Section 409A Delayed Payment Requirements.
Notwithstanding any provision to the contrary in this Agreement or in any employee plan or other agreement, plan, policy or program of the Company, any payment otherwise required to be made to Executive on account of termination of Employment
(including, without limitation, payments and benefits payable under Section 3 hereof), to the extent such payment is properly treated as deferred compensation subject to Section 409A of the Code and the regulations and other applicable
guidance issued by the Internal Revenue Service thereunder, shall be delayed until the first business day after the expiration of six months from the date of the termination of Executive’s Employment or, if earlier, the date of Executive’s
death. On the delayed payment date, there shall be paid to Executive (or Executive’s estate, as the case may be) in a single cash payment an amount equal to the aggregate amount of the payments delayed pursuant to the preceding sentence.
Notwithstanding the foregoing, Executive shall be solely responsible, and the Company shall have no liability, for any taxes, acceleration of taxes, interest or penalties arising under Section 409A of the Code. 
  

 - 7 - 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above written.

  

			
	MEDIDATA SOLUTIONS, INC.
		
	By:	 	  

	
	  

	Executive

  

 - 8 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00159-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00159-of-00352.parquet"}]]